

Monday, December 14, 2020



EOS) wins \$34.4M contract by Commonwealth of Australia **ZLD** Zelira Therapeutics (ASX:ZLD) to sell HOPE product range in DC **CNB** Carnaby Resources (ASX:CNB) defn

Holista CollTech (ASX:HCT) launches Bioesque disinfectant

Health Care

ASX:HCT MCAP \$21.47M



Lisa Simcock
 Markets Reporter
 lisa.simcock@themarket Herald.com.au
 11 December 2020 14:15



Managing Director, Dr Rajen Manicka
 Sourced: The Edge Markets

- Holista CollTech (HCT) shares have risen after launching its Bioesque disinfectant, which is listed on the Environmental Protection Agency's 'List N'
- Bioesque is a natural disinfectant that kills COVID-19 in buildings
- Products that are listed on List N have met the criteria for use against SARS-CoV-2, the virus that causes COVID-19
- Bioesque will be used in Global Infection Control Consultants' M3 system, which will be integrated into buildings ventilation
- On the market today, Holista is up 16.7 per cent and trading at 7.7 cents per share

Holista CollTech (HCT) shares have risen after launching its 'List N' disinfectant, Bioesque, to kill COVID-19 in buildings.

Products that are listed on the Environmental Protection Agency's (EPA's) List N have met the criteria for use against SARS-CoV-2, the virus that causes COVID-19.

Laboratoire M2 will supply Bioesque for use in the M3 system, while HCT's other disinfectant, Path Away, is in the process of being registered on List N.

Like Path Away, Bioesque is a botanical 100 per cent natural disinfectant.

What is the M3 system?

The M3 system can be used as a flogging (mist or fog) solution and can be integrated with a building's heating, ventilation and air-conditioning (HVAC) system.

The M3 system was created by Holista's joint-venture partner, Global Infection Control Consultants (GICC).

Disinfectants like Bioesque will be sprayed across the buildings to kill germs. However, the disinfectants will be made only from natural ingredients, which are not harmful to humans.

"It is critical that we are able to offer a List N solution now as the market opportunity for the M3 system has never been greater," GICC President Dr Arthur V. Martin said.

"Even as a COVID-19 vaccine is being rolled out today, there will still be strong demand for solutions like M3 in the long-term given the considerable time it takes for a vaccine to be distributed to the population-at-large, and the increased focus on controlling all types of viruses in the post-COVID world," he added.

Currently, Path Away and Bioesque are the only two disinfectants that have been approved by GICC for use in the M3 System.

"It is exciting to be able to offer a List N certified solution today while GICC and Holista are in the process of additionally getting Path-Away on the EPA's List N," Holista CEO Dr Rajen Manicka said.

"Having the flexibility to offer Bioesque with the M3 system will allow us to immediately offer a fully approved solution at a time of real need," he added.

Currently, the average number of COVID-19 cases in the U.S. is close to 200,000 a day, and one American dies every 30 seconds from the disease. U.S. health officials are expecting it to get worse over Christmas.

On the market today, Holista is up 16.7 per cent and is trading for 7.7 cents per share at 12:58 pm AEDT.